Biologics Spine Prosidyan® FIBERGRAFT® Achieves High Fusion Rate in Multi-Center Clinical Study Presented at Top Neurosurgery Conference byJosh SandbergAugust 26, 2021
Biologics Regulatory Spine Prosidyan® Receives CE Mark for FIBERGRAFT® BG Family of Products byChris StewartMay 20, 2021
Biologics Spine DePuy Synthes Announces Agreement with Prosidyan to Exclusively Promote FIBERGRAFT® Family of Products for Spine Fusion Surgery byJosh SandbergMay 9, 2018
Biologics Hospitals Spine Prosidyan Announces FDA Clearance and Commercial Launch of Its FIBERGRAFT BG MATRIX for Poster-Lateral Spinal Fusion byJosh SandbergOctober 26, 2017
Biologics Spine OrthoSpineNews Interview with Charanpreet Bagga, Prosidyan’s President and CEO and Renowned Surgeon Dr. Hyun Bae byJosh SandbergOctober 20, 2017
Hospitals Spine Prosidyan Receives FDA Clearance of Its FIBERGRAFT BG Putty for Postero-Lateral Spinal Fusion byJosh SandbergJune 2, 2017
Biologics Prosidyan Announces an Exclusive Joint Collaboration and License Agreement with MO-SCI Corporation for an Exciting New Technology byJosh SandbergJune 30, 2016
Hospitals Prosidyan Announces FDA 510(k) Clearance of FIBERGRAFT BG Morsels for Postero-Lateral Spinal Fusion byJosh SandbergNovember 17, 2015
Biologics Top Stories Prosidyan™ Announces FDA 510(k) Clearance of FIBERGRAFT™BG Putty – Bone Graft Substitute byJosh SandbergApril 2, 2015
